Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (671)	5/15/2005 2:03:32 PM
From: Icebrg	Read Replies (2) of 946

The patients in the control arm had the choice of using either vinorelbine och gemcitabine. The advantage was found when compared with vinorelbine, but not with gemcitabine or the two control drugs put together. Further, there were only 32 patients in the vinorelbine subarm. I don't think we should be too excited about this result, even if CTIC tries to spin it in their favour. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next